Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612806 | 1.00 | TAS1R3 (0.36) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1612801 | 1.00 | TAS1R3 (0.36) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1613368 | 0.90 | CLK1 (0.34) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1613367 | 0.90 | CLK1 (0.34) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1613369 | 0.90 | CLK1 (0.34) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1615238 | 0.86 | CLK1 (0.35) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1615242 | 0.86 | CLK1 (0.35) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL1615240 | 0.86 | CLK1 (0.35) | TAS1R3TAS1R1CLK1 | |
| SCHEMBL12714082 | 0.86 | TAS1R3 (0.49) | TAS1R3TAS1R1 | |
| SCHEMBL13906561 | 0.83 | TAS1R3 (0.34) | TAS1R3TAS1R1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309599-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-04-14 | — | — | US | disclosed |
| US-7825267-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | TAS1R3 4191/4885TAS1R1 4097/4885CLK1 2651/4885 |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | TAS1R3 4191/4885TAS1R1 4097/4885CLK1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.